Mast Therapeutics, Inc.(NYSE Amex Equities : MSTX)
MSTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading MSTX News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.78%||71.57||1.0%||$655.39m|
|ARIA||ARIAD Pharmaceuticals, Inc.||0.02%||23.70||16.4%||$429.03m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.13%||363.41||2.5%||$362.46m|
|ALXN||Alexion Pharmaceuticals, Inc.||-1.12%||134.35||2.5%||$359.12m|
|CLVS||Clovis Oncology, Inc.||0.87%||57.11||17.9%||$163.62m|
|VRTX||Vertex Pharmaceuticals Incorporated||-1.95%||80.91||2.1%||$150.84m|
|SRPT||Sarepta Therapeutics, Inc.||-4.86%||34.23||16.8%||$106.34m|
|IONS||Ionis Pharmaceuticals, Inc.||-0.93%||46.70||8.9%||$103.74m|
|BMRN||BioMarin Pharmaceutical Inc.||-1.16%||86.15||4.9%||$100.55m|
Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.